BioArctic AB (publ)
BioArctic AB (publ) (BRCTF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for BioArctic AB (publ) (BRCTF), featuring income statements, balance sheets, and cash flow data.
BioArctic AB (publ) (BRCTF) Income Statement & Financial Overview
Review BioArctic AB (publ) BRCTF income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $101.24M | $76.63M | $49.84M | $29.64M |
| Cost of Revenue | $11.85M | $8.09M | $4.81M | $2.24M |
| Gross Profit | $89.39M | $68.55M | $45.03M | $27.40M |
| Gross Profit Ratio | $0.88 | $0.89 | $0.90 | $0.92 |
| R&D Expenses | $96.28M | $68.37M | $83.52M | $62.97M |
| SG&A Expenses | $46.49M | $26.60M | $36.94M | $38.81M |
| Operating Expenses | $142.88M | $94.62M | $120.88M | $100.50M |
| Total Costs & Expenses | $154.73M | $102.71M | $125.69M | $102.74M |
| Interest Income | $10.25M | $7.00M | $7.87M | $15.72M |
| Interest Expense | $659000.00 | $617000.00 | $460000.00 | $114000.00 |
| Depreciation & Amortization | $0.00 | $7.00M | $7.46M | $4.61M |
| EBITDA | -$43.25M | -$19.08M | -$67.97M | -$57.38M |
| EBITDA Ratio | -$0.43 | -$0.25 | -$1.36 | -$1.94 |
| Operating Income | -$53.50M | -$26.08M | -$75.84M | -$73.10M |
| Operating Income Ratio | -$0.53 | -$0.34 | -$1.52 | -$2.47 |
| Other Income/Expenses (Net) | $9.59M | $6.38M | $7.41M | $15.61M |
| Income Before Tax | -$43.91M | -$19.70M | -$68.43M | -$57.49M |
| Income Before Tax Ratio | -$0.43 | -$0.26 | -$1.37 | -$1.94 |
| Income Tax Expense | -$12.44M | -$65000.00 | -$5000.00 | $75000.00 |
| Net Income | -$31.46M | -$19.63M | -$68.42M | -$57.56M |
| Net Income Ratio | -$0.31 | -$0.26 | -$1.37 | -$1.94 |
| EPS | -$0.36 | -$0.22 | -$0.77 | -$0.65 |
| Diluted EPS | -$0.36 | -$0.22 | -$0.77 | -$0.65 |
| Weighted Avg Shares Outstanding | $88.38M | $88.36M | $88.33M | $88.32M |
| Weighted Avg Shares Outstanding (Diluted) | $88.38M | $88.36M | $88.34M | $88.32M |
The company's financials show resilient growth, with revenue advancing from $29.64M in Q1 2024 to $101.24M in Q4 2024. Gross profit remained healthy with margins at 88% in Q4 2024 compared to 92% in Q1 2024. Operating income hit -$53.50M last quarter, sustaining a consistent -53% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$43.25M. Net income dropped to -$31.46M, while earnings per share reached -$0.36. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan